Keywords: بورتِـزومیب; Bortezomib; Romidepsin; NSCLC
مقالات ISI بورتِـزومیب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: بورتِـزومیب; Multiple myeloma; Proteasome inhibitor; Therapy; Oral administration; Bortezomib; Carfilzomib; Marizomib; Ixazomib; Delanzomib;
Keywords: بورتِـزومیب; CIPN, chemotherapy-induced peripheral neuropathy; GFAP, glial fibrillary acidic protein; PBS, phosphate-buffered saline; SEM, standard error of the mean; SNL, spinal nerve ligationastrocytes; microglia; oxaliplatin; bortezomib; minocycline
Keywords: بورتِـزومیب; Multiple myeloma; Bortezomib; Resistance; Ubiquitin-proteasome system; Autoimmune diseases; Proteostasis
Keywords: بورتِـزومیب; Proteasome inhibitor; Bortezomib; Proteotoxic stress; Sensory ganglia neuron; Nucleolus; Cajal body
Keywords: بورتِـزومیب; Bortezomib; Relapsed/refractory multiple myeloma; Salvage therapy; Response; Survival; Toxicity;
Keywords: بورتِـزومیب; Allogeneic hematopoietic stem cell transplantation; Bortezomib; Donor lymphocytes; Durable remission; Mantle cell lymphoma; PEG-interferon;
Keywords: بورتِـزومیب; Bortezomib; DNA; Methylation; Myeloma; Prognosis; NFKB1;
Keywords: بورتِـزومیب; Desensitization; Plasma cell; Donor specific antibody; Solid organ transplantation; Bortezomib; Proteasome inhibition;
Keywords: بورتِـزومیب; Bortezomib; Multiple myeloma; IGF-1R; Syndecan 1;
Keywords: بورتِـزومیب; Vascular-targeted photodynamic therapy (vPDT); Verteporfin; Reactive oxygen species (ROS); Bortezomib; Ubiquitination; Apoptosis; Combination therapy;
Keywords: بورتِـزومیب; Bortezomib; Cardiac amyloidosis; Cyclophosphamide; Lenalidomide; Light chain amyloidosis;
Keywords: بورتِـزومیب; Feasibility; Outcomes research; Evidence development; Everyday practice; Real-world data; Oxaliplatin; Bortezomib;
Keywords: بورتِـزومیب; Bortezomib; Carfilzomib; Cytogenetics; Dexamethasone; Immunotherapy; Lenalidomide; Next-generation sequencing
Keywords: بورتِـزومیب; Carbonic anhydrase; Boronic acid; Bortezomib; Pathogenic fungi; Pathogenic bacteria; Drosophila melanogaster
Keywords: بورتِـزومیب; Cisplatin; Bortezomib; Mouse strain; Neurite outgrowth; Neurotoxicity; Genetic variations
Keywords: بورتِـزومیب; Bortezomib; Peripheral neuropathy; Proteasome inhibition; Neurotoxicity; Nuclear factor kappa b; Sensory neurons
Keywords: بورتِـزومیب; Hyperthermia; Cytotoxicity; Apoptosis; Bortezomib; Velcade; Blood cancer;
Discovery of novel 20S proteasome inhibitors by rational topology-based scaffold hopping of bortezomib
Keywords: بورتِـزومیب; Proteasome inhibitors; Topology-based; Scaffold hopping; Bortezomib;
Cytochalasin E increased the sensitivity of human lung cancer A549â¯cells to bortezomib via inhibition of autophagy
Keywords: بورتِـزومیب; Cytochalasin E; Autophagy; Bortezomib; Human lung cancer;
VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study
Keywords: بورتِـزومیب; Autologous stem cell transplant; Bortezomib; Hyper-CVAD; MIPI score; Non-Hodgkin lymphoma;
DANFIN functions as an inhibitor of transcription factor NF-κB and potentiates the antitumor effect of bortezomib in multiple myeloma
Keywords: بورتِـزومیب; NF-κB; DANFIN; Bortezomib; Multiple myeloma; Cell-free; Combination therapy;
Upregulation of NLRP3 via STAT3-dependent histone acetylation contributes to painful neuropathy induced by bortezomib
Keywords: بورتِـزومیب; Bortezomib; NLRP3; Painful neuropathy; STAT3; Histone acetylation;
Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma
Keywords: بورتِـزومیب; Bortezomib; Intravenous administration; Multiple myeloma; Response; Subcutaneous administration;
POEMS Syndrome
Keywords: بورتِـزومیب; POEMS syndrome; Autologous stem cell transplantation; VEGF; Lenalidomide; Thalidomide; Bortezomib;
Novel aromatic sulfonyl naphthalene-based boronates as 20S proteasome inhibitors
Keywords: بورتِـزومیب; TEA; triethylamine; THF; tetrahydrofuran; Py; pyridine; DIPEA; N,N-diisopropylethylamine; TBTU; 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate; DCM; dichloromethane; TPLM; (1R)-(S)-pinanediol-1-ammonium trifluoroacetate-3-methylbut
Proteasome Inhibitors in Waldenström Macroglobulinemia
Keywords: بورتِـزومیب; Bortezomib; Carfilzomib; Oprozomib; Ixazomib; Unfolded protein response;
Bortezomib and endocannabinoid/endovanilloid system: a synergism in osteosarcoma
Keywords: بورتِـزومیب; Endocannabinoid/Endovanilloid system; Osteosarcoma; Bortezomib; CB2; TRPV1;
What is the optimal initial management of the older MCL patient?
Keywords: بورتِـزومیب; Mantle cell lymphoma; Elderly patients; Induction therapy; Maintenance therapy; R-CHOP; Bendamustine; Cytarabine; Lenalidomide; Bortezomib; Toxicity;
Posttranslational regulation of CYP2J2 by nitric oxide
Keywords: بورتِـزومیب; 3-MA; 3-methyladenine; AA; arachidonic acid; ASC; ascorbate; Bort; bortezomib; BST; biotin-switch technique; Calp; calpeptin; CHX; cycloheximide; Dan; danazol; DMEM; Dulbecco's modified Eagle Medium; DPTA; dipropylenetriamine NONOate; EETs; epoxyeicosatri
Bortezomib for Reduction of Proteinuria in IgA Nephropathy
Keywords: بورتِـزومیب; bortezomib; IgA nephropathy; proteinuria;
BaxÎ2 sensitizes colorectal cancer cells to proteasome inhibitor-induced cell death
Keywords: بورتِـزومیب; BaxÎ2; Cell death; Proteasome inhibitors; Cancer therapy; Bortezomib; Carfilzomib;
LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity
Keywords: بورتِـزومیب; Multiple myeloma; Chromosome 17p deletions; Long noncoding RNA PRAL; Bortezomib; miR-210; BMP2;
Therapeutic targeting of PP2A
Keywords: بورتِـزومیب; Protein phosphatase 2A; PP2A; SET; CIP2A; PME-1; LCMT-1; FTY720; OP449; Bortezomib; Erlotinib; Celastrol; ABL-127; SMAPs; Phenothiazines; LB-100; Protein phosphatases; Drug development; Cancer; Cell signaling; Tumor suppressors;
Progress curve analysis of the kinetics of slow-binding anticancer drug inhibitors of the 20S proteasome
Keywords: بورتِـزومیب; Bortezomib; Proteasome; Carfilzomib; Slow-binding; Ixazomib; Inhibitor; EDTA; ethylenediaminetetraacetic acid; HEPES; 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid; Suc-LLVY-AMC; N-succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin; λEx and λEm; exc
Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study
Keywords: بورتِـزومیب; Autologous stem cell transplantation; Bortezomib; Light chain amyloidosis;
Green Nanotechnology for Synthesis and characterization of poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) nanoparticles for sustained bortezomib release using supercritical CO2 assisted particle formation combined with electrodeposition
Keywords: بورتِـزومیب; Electrospraying; Carbon dioxide assisted nebulization-electro-deposition (CAN-ED); Bortezomib; Poly(3-hydroxybutyrate-co-3-hydroxyhexanoate);
Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma
Keywords: بورتِـزومیب; CD38; Bortezomib; Endocytosis; Nanoparticles, multiple myeloma;
Mechanisms controlling the multistage post-translational processing of endogenous Nrf1α/TCF11 proteins to yield distinct isoforms within the coupled positive and negative feedback circuits
Keywords: بورتِـزومیب; Nrf1; DDI-1/2; p97; Proteoform; Proteasome; Post-Translational Modification; Proteolysis; ER Stress; Hrd1; BTZ; bortezomib; CNC; cap 'n' collar; CHX; cycloheximide; DDI-1; DNA-damage inducible protein homolog 1; Epox; expoxomicin; ER; endoplasmic reticulu
Short CommunicationSuccessful combined targeting of B- and plasma cells in treatment refractory anti-NMDAR encephalitis
Keywords: بورتِـزومیب; Anti-N-methyl-d-aspartate receptor encephalitis; Immunomodulatory therapy; Bortezomib; Tocilizumab;
Allogeneic: AdultCalcineurin and mTOR Inhibitor-Free Post-Transplantation Cyclophosphamide and Bortezomib Combination for Graft-versus-Host Disease Prevention after Peripheral Blood Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I/II Study
Keywords: بورتِـزومیب; Allogeneic hematopoietic stem cell transplantation; Graft-versus-host disease prophylaxis; Post-transplantation cyclophosphamide; Bortezomib;
AutologousOutcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma
Keywords: بورتِـزومیب; Multiple myeloma; Maintenance therapy; Bortezomib; Autologous stem cell transplantation;
Research PaperActivation of RAGE/STAT3 pathway by methylglyoxal contributes to spinal central sensitization and persistent pain induced by bortezomib
Keywords: بورتِـزومیب; Bortezomib; Methylglyoxal; Persistent pain; RAGE; STAT3;
Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease
Keywords: بورتِـزومیب; ARGX-110; Brentuximab vedotin; Bortezomib; Copanlisib; cutaneous T-cell lymphoma; Forodesine; Gemcitabine; HDAC inhibitors; Ipilimumab; IPH4102; Mogamulizumab; Nivolumab; NM-IL-12; Panobinostat; Pegylated liposomal doxorubicin; Pentostatin; Pralatrexate;
Metformin triggers apoptosis in PEL cells and alters bortezomib-induced Unfolded Protein Response increasing its cytotoxicity and inhibiting KSHV lytic cycle activation
Keywords: بورتِـزومیب; AMPK; AMP-activated protein kinase; ATF4; Activating Transcription Factor 4; ATF6; Activating Transcription Factor 6; BAF; Bafilomycin A1; BiP (GRP78); Binding immunoglobulin Protein (78Â kDa glucose regulated protein); BZ; bortezomib; CHOP; C/EBP-Homolog
PEGylated thermosensitive lipid-coated hollow gold nanoshells for effective combinational chemo-photothermal therapy of pancreatic cancer
Keywords: بورتِـزومیب; Gold nanoshell; Gemcitabine; Bortezomib; Combination; Pancreatic cancer;
Original ArticleGRP78 inhibition enhances ATF4-induced cell death by the deubiquitination and stabilization of CHOP in human osteosarcoma
Keywords: بورتِـزومیب; Osteosarcoma; ATF4; GRP78; CHOP; Ubiquitination; ATF4; activating transcription factor 4; BTZ; bortezomib; CFDA SE; carboxyfluorescein diacetate succinimidyl ester; CHOP; CCAAT/enhancer-binding protein (C/EBP) homologous protein; CHX; cycloheximide; DDIT3
Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses
Keywords: بورتِـزومیب; Multiple myeloma; Bortezomib; Lenalidomide; Thalidomide; Meta-analysis; Systematic review; Quality assessment;
Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical Versions) and NCI CTCAE v4.0 in Newly Diagnosed Patients With Multiple Myeloma Receiving Bortezomib-Based Induction
Keywords: بورتِـزومیب; Bortezomib; Neuropathic pain; Neuropathy assessment; Peripheral neuropathy; Total Neuropathy Score;
Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients
Keywords: بورتِـزومیب; Biomarkers; Bortezomib; Mass spectrometry; Proteomics;